Singapore Institute of Advanced Medicine Holdings Ltd. (SGX:9G2)
Singapore
· Delayed Price · Currency is SGD
0.0280
0.00 (0.00%)
At close: Jun 24, 2025
SGXC:9G2 Income Statement
Financials in millions SGD. Fiscal year is July - June.
Millions SGD. Fiscal year is Jul - Jun.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| Revenue | 16.14 | 16.65 | 16.23 | 13.81 | 12.92 |
| Revenue Growth (YoY) | 16.86% | 2.54% | 17.56% | 6.90% | - |
| Cost of Revenue | 8.41 | 7.83 | 6.37 | 5.17 | 4.88 |
| Gross Profit | 7.73 | 8.82 | 9.87 | 8.64 | 8.04 |
| Selling, General & Admin | 11.39 | 11.47 | 11.95 | 11.56 | 8.86 |
| Other Operating Expenses | 4.87 | 5.62 | 5.97 | 5.14 | 2.7 |
| Operating Expenses | 28.71 | 29.55 | 23.69 | 21.95 | 16.7 |
| Operating Income | -20.99 | -20.73 | -13.83 | -13.32 | -8.66 |
| Interest Expense | -3.64 | -11.22 | -2.25 | -1.03 | -1.03 |
| Interest & Investment Income | 0.03 | 0.04 | 0.03 | 0.02 | 0.03 |
| Currency Exchange Gain (Loss) | -0.01 | -0.01 | 0.02 | -0.43 | 0.44 |
| Other Non Operating Income (Expenses) | -6.33 | -7.28 | -3 | -0.16 | -0.16 |
| EBT Excluding Unusual Items | -30.93 | -39.2 | -19.03 | -14.92 | -9.39 |
| Gain (Loss) on Sale of Assets | 0.01 | 0.01 | -0 | 0.44 | - |
| Other Unusual Items | 2.05 | 1.75 | 0.06 | - | - |
| Pretax Income | -28.87 | -37.44 | -18.96 | -14.48 | -9.39 |
| Earnings From Continuing Operations | -28.87 | -37.44 | -18.96 | -14.48 | -9.39 |
| Earnings From Discontinued Operations | -0.01 | -0.01 | 0.89 | 2.05 | 0.04 |
| Net Income | -28.87 | -37.45 | -18.07 | -12.43 | -9.35 |
| Net Income to Common | -28.87 | -37.45 | -18.07 | -12.43 | -9.35 |
| Shares Outstanding (Basic) | 1,006 | 823 | 679 | 645 | 533 |
| Shares Outstanding (Diluted) | 1,006 | 823 | 679 | 645 | 533 |
| Shares Change (YoY) | 55.94% | 21.15% | 5.25% | 21.04% | - |
| EPS (Basic) | -0.03 | -0.05 | -0.03 | -0.02 | -0.02 |
| EPS (Diluted) | -0.03 | -0.05 | -0.03 | -0.02 | -0.02 |
| Free Cash Flow | -14.56 | -13.46 | -17.68 | -9.89 | -7.87 |
| Free Cash Flow Per Share | -0.01 | -0.02 | -0.03 | -0.01 | -0.01 |
| Gross Margin | 47.88% | 52.99% | 60.78% | 62.54% | 62.22% |
| Operating Margin | -130.05% | -124.56% | -85.17% | -96.43% | -67.06% |
| Profit Margin | -178.93% | -224.95% | -111.32% | -89.98% | -72.38% |
| Free Cash Flow Margin | -90.25% | -80.88% | -108.89% | -71.66% | -60.94% |
| EBITDA | -11.47 | -11.22 | -10.99 | -11.01 | -6.62 |
| EBITDA Margin | -71.08% | -67.41% | -67.71% | -79.74% | -51.28% |
| D&A For EBITDA | 9.52 | 9.51 | 2.83 | 2.31 | 2.04 |
| EBIT | -20.99 | -20.73 | -13.83 | -13.32 | -8.66 |
| EBIT Margin | -130.05% | -124.56% | -85.17% | -96.43% | -67.06% |
| Advertising Expenses | - | 0.29 | 0.23 | - | - |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.